Revance Therapeutics, Inc. (RVNC) — Stock Trend Analysis

Adjust Comment Print

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 2nd. The SI to SM Energy Company's float is 18.83%. The stock traded within a range of $33.00 and $37.20. 85,509 shares of the company traded hands.

Many analysts have provided their estimated foresights on Revance Therapeutics, Inc.


Attunity Ltd. (NASDAQ:ATTU)'s market cap, the total dollar value of all of their outstanding shares, is 123.10m.

The stock increased 2.16% or $0.75 during the last trading session, reaching $35.5. About 180,028 shares traded or 171.07% up from the average. Crown Castle International Corp. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since December 6, 2016 and is uptrending. It has underperformed by 41.10% the S&P500.


Investors sentiment decreased to 1.31 in Q2 2017. Its up 0.25, from 1.09 in 2017Q1. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. 80 funds opened positions while 235 raised stakes. American Registered Advisor, Texas-based fund reported 8,090 shares. The United Kingdom-based Gsa Capital Partners Llp has invested 0.01% in the stock. Jennison Assoc Llc owns 378,400 shares. The High end of the forecast is $-0.89 per share, while the Low end is $-1.02 per share. Granite Prtn Ltd Liability has 67,961 shares. Next Fincl Gru owns 3,191 shares. Ameritas Investment Ptnrs Inc holds 1,969 shares or 0% of its portfolio. Victory Capital Management Inc stated it has 34,875 shares or 0% of all its holdings. Captrust Advsrs has 66 shares for 0% of their portfolio. Cowen & Co maintained the stock with "Outperform" rating in Monday, April 25 report. The stock of Crown Castle International Corp. (NASDAQ:RVNC) for 200 shares. Aegis Capital has "Buy" rating and $3600 target. As per Tuesday, June 6, the company rating was maintained by Williams Capital Group. The firm has "Buy" rating given on Monday, November 23 by Guggenheim. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company's stock worth $1,998,000 after purchasing an additional 38,621 shares during the period.

A number of hedge funds have recently added to or reduced their stakes in RVNC. Moreover, Creative Planning has 0% invested in Revance Therapeutics, Inc. During the same quarter last year, the firm earned ($0.64) earnings per share. research analysts anticipate that Revance Therapeutics Inc will post -3.73 earnings per share for the current year. (NASDAQ:RVNC) or 33,897 shares. Ing Groep Nv accumulated 11,909 shares. Nikko Asset Mgmt Americas Inc has invested 0.47% of its portfolio in SM Energy Company (NYSE:SM).


Revance Therapeutics (NASDAQ:RVNC) has been assigned a $50.00 price objective by Cantor Fitzgerald in a report released on Tuesday. Virginia Retirement Et Al reported 136,119 shares. Renaissance Lc accumulated 110,373 shares. Bancorporation Of Montreal Can invested in 91,683 shares. (NASDAQ:RVNC) or 5,753 shares. Deutsche State Bank Ag has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Bnp Paribas Arbitrage reported 0% stake. Trexquant Investment LP acquired a new stake in shares of Revance Therapeutics in the second quarter worth $231,000. (NASDAQ:RVNC) for 13,312 shares. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. A score above three means the company is not likely to go bankrupt, while score less than 1.8 suggests the firm is probably headed for bankruptcy. It now has negative earnings. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. Revance Therapeutics now has a consensus rating of "Buy" and an average price target of $34.86. Therefore 90% are positive. Zacks Investment Research downgraded shares of Revance Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 12th. (NASDAQ:RVNC) has "Buy" rating given on Thursday, July 20 by Cantor Fitzgerald. The stock of Revance Therapeutics, Inc. The company was initiated on Wednesday, March 23 by SunTrust. Brean Capital downgraded the stock to "Hold" rating in Tuesday, June 14 report. The rating was initiated by Cantor Fitzgerald with "Hold" on Wednesday, December 23. They set an outperform rating and a $34.00 price objective for the company. The company was maintained on Thursday, November 16 by Cantor Fitzgerald. (NASDAQ:RVNC) on Thursday, July 20 with "Buy" rating. The rating was initiated by Aegis Capital on Tuesday, November 29 with "Buy".

Comments